VENLAFAXINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Venlafaxine Hydrochloride, and what generic alternatives are available?

Venlafaxine Hydrochloride is a drug marketed by Alembic, Anchen Pharms, Annora Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Granules, Inventia Hlthcare, Macleods Pharms Ltd, Nostrum Pharms Llc, Orbion Pharms, Pharmobedient, Platinum, Sciegen Pharms, Teva, Torrent, Valeant Pharms North, Yichang Humanwell, Zydus Pharms Usa Inc, Abon Pharms Llc, Adaptis, Ajanta Pharma Ltd, Alkem Labs Ltd, Ascent Pharms Inc, Cadila Pharms Ltd, Dexcel, Mpp Pharma, Osmotica Pharm Us, Pharmadax, Somerset Theraps Llc, Sun Pharm, Unique, Zydus Pharms, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Chartwell Rx, Heritage, Pliva Hrvatska Doo, Prinston Inc, Sun Pharm Inds Inc, Yaopharma Co Ltd, and Zydus Pharms Usa. and is included in forty-seven NDAs.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Venlafaxine Hydrochloride

A generic version of VENLAFAXINE HYDROCHLORIDE was approved as venlafaxine hydrochloride by TEVA on August 3^rd, 2006.

Summary for VENLAFAXINE HYDROCHLORIDE

US Patents:	0
Applicants:	42
NDAs:	47
Finished Product Suppliers / Packagers:	61
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	218
Patent Applications:	2,494
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VENLAFAXINE HYDROCHLORIDE
What excipients (inactive ingredients) are in VENLAFAXINE HYDROCHLORIDE?	VENLAFAXINE HYDROCHLORIDE excipients list
DailyMed Link:	VENLAFAXINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VENLAFAXINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tongji Hospital	NA
Anhui Medical University	PHASE2
Lakshmi N Yatham	PHASE3

See all VENLAFAXINE HYDROCHLORIDE clinical trials

Pharmacology for VENLAFAXINE HYDROCHLORIDE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for VENLAFAXINE HYDROCHLORIDE

Antidepressive Agents, Second-Generation

Serotonin and Noradrenaline Reuptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VENLAFAXINE HYDROCHLORIDE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for VENLAFAXINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VENLAFAXINE HYDROCHLORIDE	Extended-release Tablets	venlafaxine hydrochloride	225 mg	022104	1	2011-01-10
VENLAFAXINE HYDROCHLORIDE	Extended-release Tablets	venlafaxine hydrochloride	37.5 mg, 75 mg and 150 mg	022104	1	2009-02-12
EFFEXOR XR	Extended-release Tablets	venlafaxine hydrochloride	37.5 mg, 75 mg and 150 mg	020699	1	2007-05-03
EFFEXOR	Tablets	venlafaxine hydrochloride	25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg	020151	1	2005-11-03

US Patents and Regulatory Information for VENLAFAXINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cadila Pharms Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211323-003	Aug 29, 2019	AB	RX	No	No
Alembic Pharms Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	078932-001	Dec 14, 2010	AB	RX	No	No
Teva	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	076565-002	Jun 28, 2010	AB	RX	No	No
Pharmobedient	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	078789-002	Jun 1, 2011		DISCN	No	No
Zydus Pharms Usa	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	077653-003	Jun 13, 2008	AB	RX	No	No
Teva	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	076690-003	Aug 3, 2006	AB	RX	No	Yes
Sun Pharm	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	091272-002	Aug 18, 2010		DISCN	No	No

Expired US Patents for VENLAFAXINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-002	May 20, 2008	6,419,958
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-003	May 20, 2008	6,419,958
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-001	May 20, 2008	6,403,120
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-002	May 20, 2008	6,403,120
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-004	May 20, 2008	6,403,120
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-003	May 20, 2008	6,403,120
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-001	May 20, 2008	6,419,958

International Patents for VENLAFAXINE HYDROCHLORIDE

See the table below for patents covering VENLAFAXINE HYDROCHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	006519	FORMULA ENCAPSULADA DE LIBERACION PROLONGADA DE CLORHIDRATO DE VENLAFAXINA, UNA FORMULA DE PELICULA DE RECUBRIMIENTO, Y EL USO DE DICHA FORMULA ENCAPSULADAPARA PREPARAR UNA FORMULACION DE LIBERACION PROLONGADA
Argentina	014012	FORMULA DE LIBERACION PROLONGADA
Austria	237320
Austria	257011
Australia	1300399
Australia	1640097
Australia	727653

Venlafaxine Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is venlafaxine hydrochloride and how does it monetize?

Venlafaxine hydrochloride is the salt form used for the antidepressant drug venlafaxine. In practice, the commercial market monetizes through oral solid formulations, primarily:

• Immediate-release (IR) tablets
• Extended-release (ER) capsules (commonly marketed under the branded name Effexor XR historically)

Pricing and revenue profile are driven by (1) loss of exclusivity for major originator products, (2) high substitutability between manufacturers, and (3) persistence of demand for long-term depression and anxiety treatment where physicians keep patients stable on an established regimen.

What market dynamics shaped sales over time?

1) Exclusivity end and rapid generic penetration

Venlafaxine products entered a generic-heavy market after originator exclusivity periods ended. This dynamic typically produces:

• Lower branded unit prices after generic entry
• Shift in volume share to low-cost manufacturers
• Margin pressure across the category, with revenue sustaining primarily through continued patient demand rather than innovation-led price expansion

2) Formulation mix steers unit economics

The ER category (Effexor XR-style dosing) usually commands pricing power versus IR because it matches clinician preference for once-daily adherence. However, once generics arrive, ER pricing compresses toward IR economics while still retaining a mix premium.

3) Demand stability from chronic indications

Venlafaxine is used for:

• Major depressive disorder
• Generalized anxiety disorder
• Panic disorder
• Other anxiety-spectrum indications depending on labeling and jurisdiction

Chronic treatment patterns reduce churn. That stability supports revenue longevity even when competitive pricing erodes netbacks.

How does competition translate into pricing and share?

Generic substitution mechanics

In most mature markets, venlafaxine IR and ER are interchangeable at the active-ingredient level, with differences centered on release profile, bioequivalence, and manufacturer quality systems rather than therapeutic effect. That creates a repeatable competitive outcome:

• Price erosion after first generic launch
• Further price compression as additional ANDA approvals enter
• Typical dominance of lowest total-cost suppliers, especially where payers use formulary tiering

Manufacturing and compliance costs become the main differentiator

Since the drug substance is mature, the competitive differentiators that survive scale pressures are:

• Batch yield and cost of goods
• Stability and shelf-life management for solid oral products
• Regulatory quality systems that limit supply disruptions

What does the financial trajectory look like for an incumbent vs. generic suppliers?

Originator (historical branded profile)

After exclusivity loss, originator economics typically shift from:

• Higher net price and protected demand to
• Lower net price and declining share

Even when branded volumes hold up temporarily via inertia, the long-run trend favors generics.

Generic manufacturers

Generic suppliers typically monetize through:

• Scale production and procurement economics
• Formulation-specific supply reliability (ER vs IR)
• Competitive tendering with wholesalers and payers

In mature segments, generic profits track volume and production efficiency more than pricing power.

Where does venlafaxine sit in the antidepressant competitive set?

Venlafaxine competes broadly with:

• SSRIs (e.g., sertraline, fluoxetine)
• SNRIs (e.g., duloxetine, desvenlafaxine)
• Tricyclics and other legacy agents in some markets
• Emerging branded agents in specific geographies for depression and anxiety care

In that landscape, venlafaxine’s market position remains anchored by:

• Long clinical familiarity
• Generic availability
• Clinician comfort with switching stable patients between formulations if needed

What are the main revenue drivers for venlafaxine hydrochloride?

Volume

• Stable patient populations for depression and anxiety
• Ongoing clinician prescribing in established care pathways
• Switching within class due to tolerability and cost

Net price

• Generic competition lowers net price over time
• ER mix sustains pricing relative to IR but still compresses versus branded era

Payer dynamics

• Formularies and step-therapy protocols influence uptake but often do not eliminate use given therapeutic familiarity and low cost of generics
• Bulk purchasing and tendering influence supplier ranking

How does regulatory and patent status shape trajectory?

Regulatory lifecycle: mature, generic-enabled

Venlafaxine’s market is best characterized as post-patent and post-expiry, with revenue now governed by generic competition rather than exclusivity.

Clinical utility supports durability

Clinical utility supports continued prescribing. That drives a “steady but constrained” financial trajectory:

• Revenue can remain meaningful as long as usage persists
• Growth is typically limited because incremental innovation is not a driver once generics predominate

What does the label and mechanism imply for demand persistence?

Venlafaxine is an SNRI. Its pharmacology supports use where:

• Dual monoamine modulation is a clinician preference
• Prior medication responses or tolerability profiles favor venlafaxine

Demand persistence is driven by the combination of chronic indications and established treatment pathways rather than rapid switching cycles.

What financial and market outcomes typically follow in mature venlafaxine lines?

Expected trajectory pattern

For a mature, genericized antidepressant salt:

• Short-term: revenue stays resilient due to existing patient base
• Medium-term: net revenue per unit compresses as more generic suppliers enter
• Long-term: revenue becomes a function of total prescriptions and supply chain execution, not pricing power

Profitability profile

• Branded originators: margin compression and declining share after generic entry
• Generics: profitability depends on manufacturing scale, sourcing costs, and customer contract terms
• Supply risk: shortages or quality incidents can temporarily disrupt volume and create short-lived pricing rebounds, but they rarely reset structural economics

Where are the biggest levers for revenue protection?

In a mature generic market, leverage concentrates in:

• Formulation reliability (ER supply continuity)
• Contracting and formulary retention with payers
• Cost-down through process optimization and scale
• Portfolio coverage (IR and ER to match prescriber and payer preferences)

Is there evidence of shifting demand by formulation (IR vs ER)?

Broadly, ER formulations tend to carry a mix premium because once-daily dosing improves adherence. Over time, as generics normalize the price difference, the mix shifts are typically driven by:

• Formulary positioning
• Patient adherence and tolerability experiences
• Switchbacks after side effect management

In a stable market, those shifts influence revenue mix but do not restore branded-era pricing.

Key takeaways on market dynamics and financial trajectory

• Venlafaxine hydrochloride’s commercial outcome is dominated by generic competition after exclusivity expiration, with pricing compression as the structural baseline.
• Demand durability from chronic depression and anxiety indications supports revenue continuity even as net price declines.
• ER vs IR mix is the primary controllable driver for unit economics in a mature competitive environment.
• Supplier performance (cost, quality, and supply reliability) becomes the main determinant of financial results for generic manufacturers.

---

FAQs

How long can venlafaxine generate revenue after exclusivity ends?

For antidepressants with durable indications and entrenched prescribing, revenue can remain stable for years under generic pricing, with growth limited to volume and mix.

Does extended-release materially improve economics versus immediate-release?

ER usually holds a mix premium because of adherence and clinician preference, but generic entry compresses net price so the premium reflects mix more than branded-like pricing.

What most affects net sales for generic venlafaxine products?

Net sales track contract terms, pharmacy and payer uptake, supply reliability, and manufacturing cost efficiency more than product differentiation.

Do clinical guidelines increase or reduce venlafaxine prescribing risk?

Guidelines can shift relative prescribing among antidepressants, but venlafaxine generally retains utility because it remains a well-established SNRI option and is cost-effective in generic form.

What event would most likely change venlafaxine’s financial trajectory quickly?

A significant supply disruption across major manufacturers, or a large-scale payer formulary move, can alter pricing and volume temporarily. Structural change typically requires exclusivity, formulation reentry, or major regulatory shifts.

---

References

[1] FDA. “Label Information for Venlafaxine Hydrochloride.” U.S. Food and Drug Administration, Drug Label and Registration Information. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). “Venlafaxine: Assessment and Public Documents.” European Medicines Agency. https://www.ema.europa.eu/
[3] National Library of Medicine. “Venlafaxine.” PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/
[4] U.S. Patent and Trademark Office (USPTO). “Patent Full-Text and Image Database (PatFT/ AppFT).” https://patft.uspto.gov/